Media stories about Aradigm Corporation (NASDAQ:ARDM) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aradigm Corporation earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.8305067555661 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several research firms have recently weighed in on ARDM. Zacks Investment Research downgraded Aradigm Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, August 24th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $10.00 price target (up previously from $7.50) on shares of Aradigm Corporation in a research note on Monday, September 25th.
Aradigm Corporation (ARDM) traded up $0.12 during mid-day trading on Tuesday, hitting $3.72. The stock had a trading volume of 101,100 shares, compared to its average volume of 153,829. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of -1.59. Aradigm Corporation has a 12 month low of $0.78 and a 12 month high of $5.68.
Aradigm Corporation (NASDAQ:ARDM) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.05. The company had revenue of $2.73 million during the quarter. Aradigm Corporation had a negative return on equity of 665.03% and a negative net margin of 118.37%. equities analysts forecast that Aradigm Corporation will post -0.74 EPS for the current year.
WARNING: This report was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://sportsperspectives.com/2017/11/14/aradigm-corporation-ardm-receiving-somewhat-positive-news-coverage-analysis-finds.html.
About Aradigm Corporation
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.